Ignite Creation Date:
2024-05-05 @ 5:07 PM
Last Modification Date:
2024-10-26 @ 9:28 AM
Study NCT ID:
NCT00391924
Status:
COMPLETED
Last Update Posted:
2006-10-25
First Post:
2006-10-24
Brief Title:
Dehydroepiandrosterone Administration in Women With Systemic Lupus Erythematosus or Primary Sjögrens Syndrome
Sponsor:
UMC Utrecht
Organization:
UMC Utrecht
Study Overview
Official Title:
Fatigue and General Well-Being in Patients With Systemic Lupus Erythematosus or Primary Sjögrens Syndrome Effects of Dehydroepiandrosterone Administration
Status:
COMPLETED
Status Verified Date:
2006-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of the study is to examine whether dehydroepiandrosterone DHEA administration improves fatigue and general well-being in patients with systemic lupus erythematosus or primary Sjögrens syndrome
Detailed Description:
Fatigue and reduced general well-being are frequent complaints in patients with the chronic autoimmune disorder systemic lupus erythematosus SLE or primary Sjögrens syndrome pSS Uncontrolled studies suggested that the administration of dehydroepiandrosterone DHEA may improve such complaints The aim of our randomized double-blind placebo-controlled study is to examine the effect of daily oral 200 mg DHEA on fatigue well-being and functioning in women with SLE or pSS
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None